503155-66-6 Usage
Uses
Used in Pharmaceutical Applications:
C46H44N6O3 is used as a potential pharmaceutical compound for its possible biological activities and therapeutic effects. C46H44N6O3's complex structure and composition may contribute to its potential use in the development of new drugs or treatments.
Used in Polymer Research:
C46H44N6O3 is used as a research compound in the field of polymer science. Its unique molecular structure may provide insights into the development of new polymer materials with specific properties and applications.
Used in Research and Development:
C46H44N6O3 is used as a research compound in various scientific fields, including chemistry, biology, and materials science. Its complex nature may offer opportunities for the discovery of new properties and applications, contributing to the advancement of knowledge in these areas.
Check Digit Verification of cas no
The CAS Registry Mumber 503155-66-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,3,1,5 and 5 respectively; the second part has 2 digits, 6 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 503155-66:
(8*5)+(7*0)+(6*3)+(5*1)+(4*5)+(3*5)+(2*6)+(1*6)=116
116 % 10 = 6
So 503155-66-6 is a valid CAS Registry Number.
503155-66-6Relevant academic research and scientific papers
Kim, Tae Woo,Yoo, Byoung Wook,Lee, Joon Kwang,Kim, Ji Han,Lee, Kyung-Tae,Chi, Yong Ha,Lee, Jae Yeol
, p. 1649 - 1654 (2012)
The discovery, in vitro and in vivo studies of the highly potent AT1 antagonist 12a (BR-A-657, Fimasartan) are presented. A series of pyrimidin-4(3H)-one derivatives as losartan analogue were synthesized and evaluated for a novel class of AT1 receptor antagonists. Among them, 12a containing thioamido moiety displayed both high in vitro functional antagonism and binding affinity [IC50 = 0.42 and 0.13 nM, respectively] and inhibited strongly in vivo AngII-induced pressor response in pithed rats with an ED50 of 0.018 mg/kg. Moreover, in vivo evaluation in furosemide-treated rat and conscious renal hypertensive rat models and the pharmacokinetic study showed that 12a is a highly potent and orally active AT1 selective antagonist having stronger in vivo potency than losartan.
